Research Topics

Genomes and Genes


Rudolf A de Boer


Affiliation: University Medical Center Groningen
Country: The Netherlands


  1. Meijers W, Januzzi J, deFilippi C, Adourian A, Shah S, van Veldhuisen D, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am Heart J. 2014;167:853-60.e4 pubmed publisher
    ..6% [95% CI +19.9%-65.4%], P < .001). Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-term rehospitalization. ..
  2. Filipe M, Meijers W, Rogier van der Velde A, de Boer R. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015;443:48-56 pubmed publisher
    ..The purpose of this review was to summarize the literature and explore the potential role of galectin-3 as a biomarker in HF. ..
  3. Frenay A, Yu L, van der Velde A, Vreeswijk Baudoin I, López Andrés N, van Goor H, et al. Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. Am J Physiol Renal Physiol. 2015;308:F500-9 pubmed publisher
    ..Drugs binding to galectin-3 may be therapeutic candidates for the prevention of chronic kidney disease. ..
  4. Haver V, Verweij N, Kjekshus J, Fox J, Wedel H, Wikstrand J, et al. The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). BMC Med Genet. 2014;15:140 pubmed publisher
    ..The observed association of the 1p13.3 locus with all-cause mortality requires confirmation in further studies. ..
  5. Meijers W, van der Velde A, Pascual Figal D, de Boer R. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015;763:115-21 pubmed publisher
    ..Future studies should focus on the dynamics of galectin-3 activation after myocardial infarction, and study the possibilities to target galectin-3. ..
  6. Cannon M, Silljé H, Sijbesma J, Khan M, Steffensen K, van Gilst W, et al. LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. Diabetologia. 2016;59:634-43 pubmed publisher
    ..These findings implicate a potential protective role for LXR in targeting metabolic disturbances underlying diabetes. ..
  7. Meijers W, Maglione M, Bakker S, Oberhuber R, Kieneker L, de Jong S, et al. The Failing Heart Stimulates Tumor Growth by Circulating Factors. Circulation. 2018;: pubmed publisher
    ..A diagnosis of HF may therefore be considered a risk factor for incident cancer. ..
  8. de Leeuw A, de Boer R. Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects. Eur Heart J Cardiovasc Pharmacother. 2016;2:244-55 pubmed publisher
    ..More research and long-term follow-ups will reveal the specific influence of SGLT2 inhibition on the circulatory system and cardiovascular outcomes. ..
  9. van der Velde A, Meijers W, van den Heuvel E, Bakker S, van Gilst W, van der Harst P, et al. Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND. Int J Cardiol. 2016;222:385-390 pubmed publisher
    ..These results implicate that treatment of high blood pressure might be effective to prevent increasing galectin-3 levels and its associated conditions. ..

More Information


  1. Meijers W, Lopez Andres N, de Boer R. Galectin-3, Cardiac Function, and Fibrosis. Am J Pathol. 2016;186:2232-2234 pubmed publisher
    ..Am J Pathol 2016, 186:1114-1127). ..
  2. Meijers W, van der Velde A, de Boer R. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016;24:252-8 pubmed publisher
    ..Further, we will discuss several emerging biomarkers such as galectin-3 and suppression of tumorigenicity 2, and recently discovered ones such as growth differentiation factor-15 and syndecan-1. ..
  3. Meijers W, Hoekstra T, Jaarsma T, van Veldhuisen D, de Boer R. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24:287-95 pubmed publisher
    ..Among the patients with clinically diagnosed HFpEF, those with low BNP are strikingly similar to those with elevated BNP levels, except for BMI, which was significantly higher in these patients. ..
  4. Cannon M, van Gilst W, de Boer R. Emerging role of liver X receptors in cardiac pathophysiology and heart failure. Basic Res Cardiol. 2016;111:3 pubmed publisher
    ..Taken together, the accumulating evidence supports the notion that LXRs may represent a novel therapeutic target for the treatment of heart failure. ..
  5. van der Velde A, Lexis C, Meijers W, van der Horst I, Lipsic E, Dokter M, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50-7 pubmed publisher
    ..The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI. ..
  6. Meems L, Mahmud H, Buikema H, Tost J, Michel S, Takens J, et al. Parental vitamin D deficiency during pregnancy is associated with increased blood pressure in offspring via Panx1 hypermethylation. Am J Physiol Heart Circ Physiol. 2016;311:H1459-H1469 pubmed publisher
    ..Parental vitamin D deficiency is associated with epigenetic changes and increased blood pressure levels in offspring. ..
  7. de Boer R, Schroten N, Bakker S, Mahmud H, Szymanski M, van der Harst P, et al. Plasma renin and outcome in the community: data from PREVEND. Eur Heart J. 2012;33:2351-9 pubmed publisher
    ..Plasma renin concentration is associated with an increased risk for CV events in a community-based cohort not on antihypertensive medication. ..
  8. de Boer R, van Veldhuisen D, Gansevoort R, Muller Kobold A, van Gilst W, Hillege H, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012;272:55-64 pubmed publisher
    ..Galectin-3 is associated with age and risk factors of CV disease, with a strong gender interaction for these correlations. Galectin-3 predicts all-cause mortality in the general population. ..
  9. Suthahar N, Meijers W, Brouwers F, Heerspink H, Gansevoort R, van der Harst P, et al. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population. Int J Cardiol. 2018;250:188-194 pubmed publisher
    ..This suggests that other, indirect, pathophysiological mechanisms related to inflammation may explain their strong relation. ..
  10. Gehlken C, Suthahar N, Meijers W, de Boer R. Galectin-3 in Heart Failure: An Update of the Last 3 Years. Heart Fail Clin. 2018;14:75-92 pubmed publisher
    ..In summary, galectin-3 is a biomarker and biotarget in cardiac remodeling and fibrosis and future research will target galectin-3-centered diseases. ..
  11. Cannon M, Silljé H, Sijbesma J, Vreeswijk Baudoin I, Ciapaite J, van der Sluis B, et al. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. EMBO Mol Med. 2015;7:1229-43 pubmed publisher
  12. Suthahar N, Meijers W, Sillje H, de Boer R. From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. Curr Heart Fail Rep. 2017;14:235-250 pubmed publisher
    ..Understanding and describing the elements of the inflammatory and fibrotic pathways are essential, and specific drugs that target these pathways need to be evaluated. ..